BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11571

543635

PPLPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

PIRAMAL PHARMA LIMITED performance

Today’s low

Today’s high

₹ 209.26 ₹ 216.37
₹ 211.05

52 week low

52 week high

₹ 136.10 ₹ 307.90
₹ 211.05

Open Price

₹ 212.00

Prev. Close

₹ 211.96

Volume (Shares)

3050996.00

Total traded value

₹ 6439.12

Upper Circuit

₹ 254.35

Lower Circuit

₹ 169.56

info

PIRAMAL PHARMA LIMITED Share Price Update

As of the latest trading session, PIRAMAL PHARMA LIMITED share price is currently at ₹ 211.05, which is down by ₹ -0.91 from its previous closing. Today, the stock has fluctuated between ₹ 209.26 and ₹ 216.37. Over the past year, PIRAMAL PHARMA LIMITED has achieved a return of 46.91 %. In the last month alone, the return has been -6.42 %. Read More...

PIRAMAL PHARMA LIMITED fundamentals


  • Market cap (Cr)

    27,920.82

  • P/E Ratio (TTM)

    40.74

  • Beta

    0.82

  • Book Value / share

    52.94

  • Return on equity

    6.53%

  • EPS (TTM)

    5.18

  • Dividend yield

    0.05%

  • Net profit/quarter (Cr)

    118.80

info icon alternate text
  • Market cap (Cr)

    27,920.82

  • P/E Ratio (TTM)

    40.74

  • Beta

    0.76

  • Book Value / share

    52.94

  • Return on equity

    6.53%

  • EPS (TTM)

    5.18

  • Dividend yield

    0.05%

  • Net profit/quarter (Cr)

    118.80

info icon alternate text

PIRAMAL PHARMA LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 1248.32
Operating Expense 1113.61
Net Profit 118.80
Net Profit Margin (%) 9.51
Earnings Per Share (EPS) 0.90
EBITDA 244.04
Effective Tax Rate (%) 25.47
Particulars SEP 2024 (Values in Cr)
Revenue 1284.39
Operating Expense 1115.06
Net Profit 210.06
Net Profit Margin (%) 16.35
Earnings Per Share (EPS) 1.59
EBITDA 359.27
Effective Tax Rate (%) 23.81
Particulars JUN 2024 (Values in Cr)
Revenue 1063.20
Operating Expense 988.30
Net Profit 85.27
Net Profit Margin (%) 8.02
Earnings Per Share (EPS) 0.64
EBITDA 188.39
Effective Tax Rate (%) 23.63
Particulars MAR 2024 (Values in Cr)
Revenue 1525.30
Operating Expense 1215.82
Net Profit 273.08
Net Profit Margin (%) 17.90
Earnings Per Share (EPS) 2.06
EBITDA 442.83
Effective Tax Rate (%) 24.70
Particulars DEC 2023 (Values in Cr)
Revenue 1024.14
Operating Expense 967.58
Net Profit 74.34
Net Profit Margin (%) 7.25
Earnings Per Share (EPS) 0.56
EBITDA 158.64
Effective Tax Rate (%) 17.08
Particulars MAR 2024 (Values in Cr)
Revenue 4390.11
Operating Expense 4084.54
Net Profit 391.22
Net Profit Margin (%) 8.91
Earnings Per Share (EPS) 3.05
EBITDA 819.98
Effective Tax Rate (%) 22.93
Particulars MAR 2023 (Values in Cr)
Revenue 3443.22
Operating Expense 3653.64
Net Profit 69.50
Net Profit Margin (%) 2.01
Earnings Per Share (EPS) 0.58
EBITDA 431.64
Effective Tax Rate (%) 43.81
Particulars MAR 2022 (Values in Cr)
Revenue 3340.42
Operating Expense 3087.80
Net Profit 367.54
Net Profit Margin (%) 11.00
Earnings Per Share (EPS) 3.12
EBITDA 684.99
Effective Tax Rate (%) 20.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 59.80
ROE % 0.22
ROCE % 5.40
Total Debt to Total Equity 0.70
EBITDA Margin 17.47
Particulars MAR 2023 (Values in Cr)
Book Value / Share 56.76
ROE % -2.77
ROCE % 1.90
Total Debt to Total Equity 0.72
EBITDA Margin 12.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 56.47
ROE % 6.11
ROCE % 6.91
Total Debt to Total Equity 0.58
EBITDA Margin 19.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 56.35
ROE % 14.90
ROCE % 12.67
Total Debt to Total Equity 0.54
EBITDA Margin 26.25
Particulars MAR 2024 (Values in Cr)
Book Value / Share 50.74
ROE % 6.53
ROCE % 8.27
Total Debt to Total Equity 0.24
EBITDA Margin 18.68
Particulars MAR 2023 (Values in Cr)
Book Value / Share 44.09
ROE % 1.34
ROCE % 3.62
Total Debt to Total Equity 0.27
EBITDA Margin 12.54
Particulars MAR 2022 (Values in Cr)
Book Value / Share 43.20
ROE % 7.97
ROCE % 9.82
Total Debt to Total Equity 0.15
EBITDA Margin 20.51
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.23
ROE % 13.94
ROCE % 16.15
Total Debt to Total Equity 0.04
EBITDA Margin 28.42
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 482.56
Total Assets 15311.81
Total Liabilities 15311.81
Total Equity 7911.37
Share Outstanding 1322948130
Price to Book Ratio 2.54
Return on Assets (%) 0.11
Return on Capital (%) 0.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 307.56
Total Assets 14522.56
Total Liabilities 14522.56
Total Equity 6773.50
Share Outstanding 1193318500
Price to Book Ratio 1.55
Return on Assets (%) -1.28
Return on Capital (%) -1.52
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 328.99
Total Assets 12797.04
Total Liabilities 12797.04
Total Equity 6696.60
Share Outstanding 1185913506
Price to Book Ratio 0.00
Return on Assets (%) 2.93
Return on Capital (%) 3.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 405.62
Total Assets 10899.78
Total Liabilities 10899.78
Total Equity 5605.00
Share Outstanding 994600000
Price to Book Ratio 0.00
Return on Assets (%) 7.66
Return on Capital (%) 9.81
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 241.73
Total Assets 9550.88
Total Liabilities 9550.88
Total Equity 6712.07
Share Outstanding 1322948130
Price to Book Ratio 2.54
Return on Assets (%) 4.09
Return on Capital (%) 4.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 64.16
Total Assets 8042.40
Total Liabilities 8042.40
Total Equity 5261.79
Share Outstanding 1193318500
Price to Book Ratio 1.55
Return on Assets (%) 0.86
Return on Capital (%) 1.01
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 137.23
Total Assets 7371.04
Total Liabilities 7371.04
Total Equity 5123.12
Share Outstanding 1185913506
Price to Book Ratio 0.00
Return on Assets (%) 4.98
Return on Capital (%) 5.86
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 152.35
Total Assets 5756.67
Total Liabilities 5756.67
Total Equity 4100.62
Share Outstanding 994600000
Price to Book Ratio 0.00
Return on Assets (%) 9.92
Return on Capital (%) 13.4
Particulars MAR 2024 (Values in Cr)
Net Income 119.80
Cash from Operations 1161.38
Cash from Investing -434.01
Cash from Financing -422.36
Net change in Cash 148.17
Free Cash Flow 1873.42
Particulars MAR 2023 (Values in Cr)
Net Income -160.56
Cash from Operations 672.89
Cash from Investing -1338.78
Cash from Financing 817.79
Net change in Cash -37.10
Free Cash Flow 1637.63
Particulars MAR 2022 (Values in Cr)
Net Income 441.03
Cash from Operations 935.84
Cash from Investing -1812.10
Cash from Financing 794.19
Net change in Cash -251.49
Free Cash Flow 1825.35
Particulars MAR 2021 (Values in Cr)
Net Income 639.68
Cash from Operations 742.09
Cash from Investing -4479.93
Cash from Financing 3976.83
Net change in Cash 94.48
Free Cash Flow 1344.28
Particulars MAR 2024 (Values in Cr)
Net Income 507.62
Cash from Operations 436.10
Cash from Investing -635.52
Cash from Financing 451.38
Net change in Cash 174.15
Free Cash Flow 761.66
Particulars MAR 2023 (Values in Cr)
Net Income 123.69
Cash from Operations 131.55
Cash from Investing -435.05
Cash from Financing 290.12
Net change in Cash -73.41
Free Cash Flow 376.41
Particulars MAR 2022 (Values in Cr)
Net Income 477.41
Cash from Operations 351.85
Cash from Investing -1245.61
Cash from Financing 896.40
Net change in Cash -100.02
Free Cash Flow 584.67
Particulars MAR 2021 (Values in Cr)
Net Income 349.11
Cash from Operations 130.01
Cash from Investing -4382.89
Cash from Financing 4494.16
Net change in Cash 145.99
Free Cash Flow 188.12
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

PIRAMAL PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
211.05 -0.42 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 214.40
  • 26 Days 217.60
  • 10 Days 216.70
  • 50 Days 218.60
  • 12 Days 217.20
  • 100 Days 221.00
  • 20 Days 217.70
  • 200 Days 211.60
212.97 PIVOT

First Support

207.70

First Resistance

217.23

Second Support

203.44

Second Resistance

222.50

Third Support

198.17

Third Resistance

226.76

RSI

43.10

ADX

7.68

MACD

-0.40

Williams % R

-81.12

Commodity Channel Index (CCI)

-118.89

Date

2025-04-30

Week

1308901.00

Same Day

1047211.00

Month

1500547.00

1 Year

0.82

3 Year

0.92

Over 1 Month

-6.42%

down

Over 1 Year

46.91%

down

Over 3 Months

-8.73%

down

Over 3 Years

4.38%

down

Over 6 Months

-16.41%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

PIRAMAL PHARMA LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
18.77%
Promoter Holdings
34.94%
FII
31.49%
DII
14.77%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
The Sri Krishna Trust Through Its Trustee Mr. Ajay G Piramal And Dr. (mrs.) Swati A Piramal 3.5289142E8 (26.62%) Shareholding of Promoter and Promoter Group
Ca Alchemy Investments 2.386637E8 (18.0%) Public Shareholding
Hdfc Trustee Company Limited-hdfc Flexi Cap Fund 1.09606497E8 (8.27%) Public Shareholding
V3 Designs Llp 4.3021826E7 (3.25%) Shareholding of Promoter and Promoter Group
Prl Realtors Llp 3.9797353E7 (3.0%) Shareholding of Promoter and Promoter Group
East Bridge Capital Master Fund I Ltd 3.4639997E7 (2.61%) Public Shareholding
Indiahold Limited 1.7299744E7 (1.3%) Public Shareholding
Canara Robeco Mutual Fund A/c Canara Robeco Small Cap Fund 1.6027333E7 (1.21%) Public Shareholding
Piramal Welfare Trust (formerly Known As The Piramal Enterprise Executives Trust) 1.0573898E7 (0.8%) Shareholding of Promoter and Promoter Group
Semplice Corporate Solutions Private Limited (aasancorporatesolutionspvtlimited) 8931097.0 (0.67%) Shareholding of Promoter and Promoter Group
The Ajay G. Piramal Foundation 4375937.0 (0.33%) Shareholding of Promoter and Promoter Group
Mr. Anand Piramal 874082.0 (0.07%) Shareholding of Promoter and Promoter Group
Anand Piramal Trust 617884.0 (0.05%) Shareholding of Promoter and Promoter Group
Nandini Piramal Trust 544325.0 (0.04%) Shareholding of Promoter and Promoter Group
Mr. Ajay G. Piramal 547326.0 (0.04%) Shareholding of Promoter and Promoter Group
Mr. Peter Deyoung 432000.0 (0.03%) Shareholding of Promoter and Promoter Group
Ms. Nandini Piramal 290418.0 (0.02%) Shareholding of Promoter and Promoter Group
Master Dev Piramal Deyoung 192000.0 (0.01%) Shareholding of Promoter and Promoter Group
Ms. Anya Piramal Deyoung 192000.0 (0.01%) Shareholding of Promoter and Promoter Group
The Hongkong And Shanghai Banking Corp.ltd. 1332.0 (0.0%) Public Shareholding
Prl Agastya Buildcon Pvt. Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Topzone Mercantile Llp (formerly Topzone Mercantile Company Llp) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Nithyam Realty Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
India Resurgence Arc Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
India Resurgence Asset Management Business Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Trusteeship Services Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Sons Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
The Gulita Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Swati Piramal Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sreekovil Realty Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Anutham Realty Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Corporate & Management Services Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mr. Ajay G. Piramal (karta Of Ajay G. Piramal Huf) 28857.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrs. Lalita G. Piramal 4936.0 (0.0%) Shareholding of Promoter and Promoter Group
Dr. (mrs.) Swati A. Piramal 9313.0 (0.0%) Shareholding of Promoter and Promoter Group
The Swastik Safe Deposit & Investments Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
The Sri Hari Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
The Sri Govinda Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
The Sri Gopikrishna Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
The Piramal Art Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Propiedades Realties Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Prl Properties Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Prl Infraconstructions & Developers Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Prl Developers Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Agastya Offices Private Limited(formerly Known As Prl Agastya Pvt. Ltd.) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Water Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Realty & Developers Pvt. Ltd. (formerly Known As Piramal Urban Transport Network Pvt Ltd) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Udgam Data Management Solutions 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Systems & Technologies Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Retail Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Residences Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Prpl Enterprises Pvt. Ltd (formerly Known As Piramal Realty Pvt. Ltd.) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Natural Resources Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Metals Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Investment Advisory Services Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal International Consultants Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Glass Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Fund Management Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Foundation For Education Leadership 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Estates Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Corporate Tower Private Limited (formerly Known As Piramal Consumer Products Pvt. Ltd.) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Commercial Estates Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Homes Pvt. Ltd. (formerly Piramal Building Material And Cement Pvt. Ltd.) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Biotech Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Enterprises Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pel Management Sevices Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pel Finhold Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pdl Realty Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pce Developers Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Nival Developers Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Piramal Corporate Services Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Montane Ventures Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kaivalya Education Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Indiaventure Advisors Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Glider Buildcon Realtors Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Alpex Infraconstructions Pvt. Ltd. 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

PIRAMAL PHARMA LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
12 Jul 2024 0.11 Final 12 Jul 2024 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Piramal Pharma Share Result Highlights

ParticularsSep 2024 (₹ Cr)Jun 2024 (₹ Cr)Mar 2024 (₹ Cr)Dec 2023 (₹ Cr)Sep 2023 (₹ Cr)
Revenue1284.391063.201525.301024.14994.24
Operating Expense1115.06988.301215.82967.58987.13
Net Profit210.0685.27273.0874.3477.16
Net Profit Margin (%)16.358.0217.907.257.76
Earnings Per Share (EPS)1.590.642.060.560.61
EBITDA359.27188.39442.83158.64175.24
Effective Tax Rate (%)23.8123.6324.7017.0819.78

Key Highlights

  • Revenue increased to ₹1284.39 Cr in Sep 2024, significantly higher than ₹1063.20 Cr in Jun 2024.
  • Net Profit saw a sharp rise to ₹210.06 Cr in Sep 2024, compared to ₹85.27 Cr in Jun 2024, showing substantial growth.
  • Net Profit Margin improved to 16.35% in Sep 2024, reflecting better profitability compared to 8.02% in Jun 2024.
  • Earnings Per Share (EPS) rose to ₹1.59 in Sep 2024, a strong improvement over ₹0.64 in Jun 2024.
  • EBITDA was ₹359.27 Cr in Sep 2024, indicating a strong operational performance.

Piramal Pharma Share Annual Reports

ParticularsValue (₹ Cr)
Revenue4390.11
Operating Expense4084.54
Net Profit391.22
Net Profit Margin (%)8.91
Earnings Per Share (EPS)3.05
EBITDA819.98
Effective Tax Rate (%)22.93

Key Highlights

  • Revenue of ₹4390.11 crore.
  • Operating expense of ₹4084.54 crore.
  • Net profit of ₹391.22 crore.
  • Net profit margin at 8.91%.
  • EPS of ₹3.05.
  • EBITDA of ₹819.98 crore.
  • Effective tax rate of 22.93%.
  • Piramal Pharma share price increased by 117.43% in the past year.

Piramal Pharma Share Dividend

ParticularsValue
Dividend Yield0.04%
Earnings Per Share (EPS)₹3.05
Net Profit₹391.22 Cr
Piramal Pharma Share Price₹273.45

Key Highlights

  • Dividend yield of 0.04%.
  • EPS of ₹3.05.
  • Net profit of ₹391.22 crore.
  • Piramal Pharma share price at ₹273.45.

PIRAMAL PHARMA LIMITED Share Price

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.

PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.

In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).

In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).

In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs.

On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022.

In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022.

In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.

In FY24, Company launched 27 new products and 24 new SKUs .

Parent organization Piramal Ajay G
NSE symbol PPLPHARMA
Founded 2020
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Piramal Pharma Ltd?

Answer Field

The share price of Piramal Pharma Ltd for NSE is ₹ 211.05 and for BSE is ₹ 211.05.

What is the Market Cap of Piramal Pharma Ltd?

Answer Field

The market cap of Piramal Pharma Ltd for NSE is ₹ 2,79,20.82 Cr. and for BSE is ₹ 2,79,20.82 Cr. as of now.

What is the 52 Week High and Low of Piramal Pharma Ltd?

Answer Field

The 52 Week High and Low of Piramal Pharma Ltd for NSE is ₹ 307.90 and ₹ 136.10 and for BSE is ₹ 307.85 and ₹ 135.85.

How to Buy Piramal Pharma Ltd share?

Answer Field

You can trade in Piramal Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Piramal Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 46.91%.

What is the Current Share Price of Piramal Pharma Ltd?

Answer Field

Piramal Pharma Ltd share price is for NSE ₹ 211.05 & for BSE ₹ 211.05 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Piramal Pharma Ltd Share?

Answer Field

The market cap of Piramal Pharma Ltd for NSE ₹ 2,79,20.82 & for BSE ₹ 2,79,20.82 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Piramal Pharma Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Piramal Pharma Ltd share is 40.74.

What is the PB ratio of Piramal Pharma Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Piramal Pharma Ltd share is 52.94.

How to Buy Piramal Pharma Ltd Share?

Answer Field

You can trade in Piramal Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Piramal Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Piramal Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Piramal Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Piramal Pharma Ltd?

Answer Field

The CEO of Piramal Pharma Ltd is Nandini Piramal. She is also the Chairperson of Piramal Enterprises Ltd, which is the parent company of Piramal Pharma Ltd. Under her leadership, the company has expanded its offerings in the pharmaceutical sector, including drug discovery, development, and manufacturing services.

When was Piramal Pharma Ltd established?

Answer Field

Piramal Pharma Ltd was incorporated on March 4, 2020, as a public limited company. The company was subsequently registered with the Registrar of Companies (RoC). It came into existence as a part of Piramal Enterprises Ltd's strategic reorganisation, which aimed to demerge its pharmaceutical business and expand its capabilities in drug manufacturing, biologics, vaccines, and self-care products.

What factors influence the Piramal Pharma Share Price?

Answer Field

The Piramal Pharma share price is influenced by various factors, including the company’s financial performance, industry growth, and global demand for pharmaceutical products. Key drivers include the company’s expansion into biologics and vaccines, joint ventures with companies like Allergan (now AbbVie), and the launch of new products. Other factors such as regulatory changes, competition in the pharmaceutical industry, and global market conditions also impact the Piramal Pharma share price.

Is Piramal Pharma Ltd debt-free?

Answer Field

No, Piramal Pharma Ltd is not debt-free. The company has undertaken strategic acquisitions and investments, which sometimes involve debt financing. However, Piramal Pharma has a strong portfolio of differentiated products and services, a global manufacturing footprint, and an expanding distribution network that support its ability to manage and service its debt.

What is the CAGR of Piramal Pharma Share?

Answer Field

The Compound Annual Growth Rate (CAGR) of the Piramal Pharma share price is not readily available for 10 years and 5 years. However, the share price has performed well over the past year, with a notable increase of 117%. This growth is indicative of the company’s positive trajectory, particularly following the demerger from Piramal Enterprises Ltd and its strategic investments and acquisitions.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|